

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1993PLC056594

Ref: STEX/Results/Published-2020-21

Date: 18.11.2020

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

**Sub. : Copy of Publication for Un-Audited Financial Results for the Half year ended
September 30, 2020**

Dear Sir,

The Board of Directors at their Meeting held on 13.11.2020 adopted the Un-Audited Financial Results of the Company for the half year ended on September 30, 2020.

The copy of the results published in the Financial Express and Jansatta dated November 14, 2020 is enclosed.


This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157



Encl: As above.

NOTICE (For Immovable property) (Rule 8(1))

Second Quarter Ended on 30th September, 2020

Particulars	Standalone		
	Quarter ended	Half year ended	Quarter ended
	30.09.2020 (unaudited)	30.09.2020 (unaudited)	30.09.2019 (unaudited)
Total income from operations (net)	13.66	25.28	12.87
Profit before tax	4.01	8.36	3.24
Profit after tax	4.01	8.36	3.24

Note:

- The above is an extract of the detailed format of unaudited Financial Results for the Half year ended and Second Quarter ended September 30th, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full formats of standalone/consolidated financial results along with notes are available on the Stock Exchange website www.bseindia.com and on Company's website www.rrfcl.com
- The above results has been prepared in compliance with recognition and measurement principles of companies (Indian accounting standards) rules, 2015 (IND AS), as amended by the companies (Indian accounting standards) (Amended rules), 2016 prescribed under section 133 of company act, 2013 and other recognised accounting practices and policies to the extent applicable.
- Previous year figures have been regrouped and rearranged wherever considered necessary. The entire operation of the company relates to only one reportable segment, therefore segment reporting by Ind AS 108 is not required.

For and on behalf of the Board of
R R Financial Consultants Limited
SD/-

Rajat Prasad
Managing Director
Din: 00062612

Date: 13th November, 2020
Place: New Delhi

9	Paid up Debt Capital / Outstanding Debt	6,653.2	5,314.6	6,938.6
10	Outstanding Redeemable Preference Shares *	-	-	-
11	Debt Equity Ratio	0.94	0.71	0.97
12	Earnings Per Share (of ₹ 10/- each) (not annualised)			
	(a) Basic :	(0.59)	0.34	(4.05)
	(b) Diluted :	(0.59)	0.33	(4.05)
13	Capital Redemption Reserve	-	-	-
14	Debenture Redemption Reserve	-	-	-
15	Debt Service Coverage Ratio	0.65	1.05	0.25
16	Interest Service Coverage Ratio	0.91	1.57	0.45

Notes :

- The above is an extract of the detailed format of standalone unaudited financial results for the half year ended September 30, 2020 filed with stock exchanges under regulation 52(4) and Regulation 52(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of unaudited standalone financial results for the half year ended 30 September 2020 are available on stock exchanges websites (www.bseindia.com) as well as on Company's website www.ncml.com.
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2020. The statutory auditors have expressed unqualified reviewed opinion.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

For and on behalf of
National Collateral Management Services Limited
CIN: U74140MH2004PLC148859

Sd/-
Siraj A. Chaudhry
Managing Director & CEO
DIN : 00161853

Date : 13 November 2020
Place : Gurugram

**MEDICAMEN BIOTECH LTD.**

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
CIN: L74899DL1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the Half Year ended on 30.09.2020

(In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Half year ended		Year Ended	Quarter Ended		Half year ended		Year Ended
		Un-audited 30.09.2020	Un-audited 30.09.2019	Un-audited 30.09.2020	Un-audited 30.09.2019	Audited 31.03.2020	Un-audited 30.09.2020	Un-audited 30.09.2019	Un-audited 30.09.2020	Un-audited 30.09.2019	Audited 31.03.2020
1	Total income from operations (net)	3090.38	3586.81	5710.31	6703.56	11925.09	3090.38	3586.81	5877.14	6703.56	12744.26
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	460.02	521.93	765.29	953.70	1660.39	460.02	521.93	783.85	953.70	1798.02
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	460.02	521.93	765.29	953.70	1660.39	460.02	521.93	783.85	953.70	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	322.36	383.72	532.85	711.85	1225.89	322.36	383.72	546.77	711.85	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	322.36	383.72	532.85	711.85	1225.89	322.36	383.72	546.77	711.85	1329.12
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs.5/- each) (for continuing and discontinued operation)										
	Basic:	2.64	3.18	4.36	5.89	10.09	2.64	3.18	4.48	5.89	10.94
	Diluted:	2.64	3.18	4.36	5.89	10.09	2.64	3.18	4.48	5.89	10.94

Note:

- The un-audited financial statement for the quarter and half year ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2020.
- The figures are regrouped in previous year also, wherever considered necessary.
- Limited Review Report has been carried out by the Statutory Auditors for the above period.

For Medicamen Biotech Limited

Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 13.11.2020

(913.87)	(1555.20)	(8957.65)
(913.87)	(1555.20)	(8957.65)
(597.51)	(1199.90)	(5871.42)
(597.51)	(1199.16)	(5870.13)
2100.00	2100.00	2100.00
(0.57)	(1.14)	(5.59)
(0.57)	(1.14)	(5.59)

by the Audit Committee and approved by November 12, 2020.

of Quarterly and Yearly Financial Results Regulation 33 of the SEBI (Listing Obligation Regulations, 2015. The full formats of the available on the website of the Stock Exchange of India and also on the website of www.nseindia.com and also on the website of www.bseindia.com

By the order of Board of Directors For Arcotech Limited
Sd/-
RN Pattanayak
Whole Time Director
Din: 01189370

	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)	(अनकक्षित)
1 प्रचालनों से कुल राजस्व	467.23	360.81	918.23	632.88	467.23	360.81	918.23	632.88	632.88
2 कर तथा असाधारण मदों से पूर्व अवधि हेतु निवल लाभ / (हानि)	151.97	87.57	276.29	175.33	151.98	87.57	276.29	175.33	175.33
3 कर पूर्व और असाधारण मदों के पश्चात अवधि हेतु निवल लाभ / (हानि)	151.97	87.57	276.29	175.33	151.98	87.57	276.29	175.33	175.33
4 कर पश्चात अवधि हेतु निवल लाभ / (हानि)	113.52	66.91	206.55	130.26	113.53	66.91	206.55	130.26	130.26
5 अवधि हेतु कुल व्यापक आय [अवधि हेतु लाभ / (हानि) (कर पश्चात) तथा अन्य व्यापक आय (कर पश्चात) सहित]	312.05	830.68	659.28	1061.59	113.53	66.91	206.55	130.26	130.26
6 प्रदत्त इविचटी शेयर पूंजी	1,473.85	1,473.85	1,473.85	1,473.85	1,473.85	1,473.85	1,473.85	1,473.85	1,473.85
7 प्रति शेयर आय									
बैसिक (₹)	2.12	0.36	4.47	2.07	0.77	0.45	1.40	0.88	0.88
डायल्यूटेड (₹)	2.12	0.36	4.47	2.07	0.77	0.45	1.40	0.88	0.88

टिप्पणी:
 1 13 नवम्बर, 2020 को आयोजित बैठक में उपरोक्त परिणामों की ऑडिट कमिटी द्वारा समीक्षा की गई है और निदेशक मंडल द्वारा अनुमोदित किया गया। विधिक लेखापरीक्षकों ने इन वित्तीय परिणामों की सीमित समीक्षा की है।
 2 उपरोक्त विवरण सेबी (एलओडीआर) विनियमन, 2015 के विनियमन 33 के अंतर्गत स्टॉक एक्सचेंजों में दाखिल किये गये 30 सितम्बर, 2020 को समाप्त तिमाही और छमाही के कंसोलिडेटेड तथा स्टैंडएलॉन वित्तीय परिणामों का विस्तृत प्रारूप का सार है। परिणामों का संपूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइट www.bseindia.com तथा कंपनी की वेबसाइट www.sonalmarcantile.in पर उपलब्ध है।

कृते सोनल मार्केटाइल लिमिटेड
हस्ताक्षर
कुरा बिशु
कंपनी सचिव

स्थान: नई दिल्ली
 तिथि: 13 नवम्बर, 2020



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
 CIN: L74899DL1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the Half Year ended on 30.09.2020 (In Lakhs)

Sl. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Half year ended		Year Ended	Quarter Ended		Half year ended		Year Ended
		Un-audited 30.09.2020	Un-audited 30.09.2019	Un-audited 30.09.2020	Un-audited 30.09.2019	Audited 31.03.2020	Un-audited 30.09.2020	Un-audited 30.09.2019	Un-audited 30.09.2020	Un-audited 30.09.2019	Audited 31.03.2020
1	Total income from operations (net)	3090.38	3586.81	5710.31	6703.56	11925.09	3090.38	3586.81	5877.14	6703.56	12744.26
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	460.02	521.93	765.29	953.70	1660.39	460.02	521.93	783.85	953.70	1798.02
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	460.02	521.93	765.29	953.70	1660.39	460.02	521.93	783.85	953.70	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	322.36	383.72	532.85	711.85	1225.89	322.36	383.72	546.77	711.85	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	-322.36	383.72	532.85	711.85	1225.89	322.36	383.72	546.77	711.85	1329.12
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs.5/- each) (for continuing and discontinued operation)										
	Basic:	2.64	3.18	4.36	5.89	10.09	2.64	3.18	4.48	5.89	10.94
	Diluted:	2.64	3.18	4.36	5.89	10.09	2.64	3.18	4.48	5.89	10.94

Note:
 1 The un-audited financial statement for the quarter and half year ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2020
 2 The figures are regrouped in previous year also, wherever considered necessary
 3 Limited Review Report has been carried out by the Statutory Auditors for the above period.

Place: New Delhi
 Date: 13.11.2020

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

3, 2020
 e data)
 ENDED
 ar-2020
 dited
 212.21
 358.34
 332.86
 70.12
 60.76
 502.74
 903.64
 2.46
 2.46
 s at their
 (Listing
 xchange
 Limited
 Sd/-
 Amit Jain
 Director
 0041300

नई दिल्ली